New blood test aims to spot prostate cancer cells earlier

NCT ID NCT01402154

Completed Diagnosis Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The results could help doctors decide on the best treatment approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EPISPOT blood test
What this could lead to: If successful, this could lead to a more accurate blood test to detect prostate cancer cells early, helping doctors choose the best treatment.
What could go wrong: This is a completed study comparing two detection methods, not a treatment trial. The test may not prove better than existing methods or may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF THE PROSTATE

Contacts and locations

Locations

CHU de Montpellier - Hôpital Lapeyronie

Montpellier, 34295, France
CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH

Montpellier, 34295, France
CHU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, Gard, 30029, France
Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque

Montpellier, 34298, France
Clinique Beau Soleil

Montpellier, 34070, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.